Continued investment in key hires to
strategically position Company for future growth and scale
ROSEVILLE, Minn., April 26,
2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq:
CLXT), a plant-based synthetic biotechnology company, yesterday
welcomed the second of two director-level hires in areas critical
to the continued advancement of the Company's key technology and
business development goals.
The first hire was Ms. Suellen
Boot who joined as Business Development Director earlier in
April. Ms. Boot brings more than twenty years of business
development expertise to Calyxt, where she will lead partnerships,
deal structuring, valuation modeling, transaction execution and alliance
management for the Company's key target markets. The second hire is
Ms. Elizabeth Teigland who joined
today as Manufacturing Director. Ms. Teigland brings over 15 years
of chemistry and purification expertise to Calyxt. She will be
responsible for leading and managing the optimization of the
Company's BioFactory Production System and play a significant role
in helping to facilitate pilot to commercial scale production of
the of customer demand-driven compounds.
"I am pleased to welcome Suellen and Elizabeth to Calyxt," said
Michael. A Carr, President and Chief Executive Officer at Calyxt.
"Their arrivals are critical for advancing two of our near-term
revenue streams: business development and BioFactory
commercialization. Each of these talented individuals bring unique
skills that equip our company for increased growth and
momentum.
Utilizing its PlantSpring™ technology platform, Calyxt
strives to enable customers to create products using plant-based
ingredients that can be used to help customers meet their
sustainability goals. "Suellen's experience is well aligned with
our strategy to deliver plant-based synthetic biotechnology
solutions to target customers in the identified key end markets of
cosmeceuticals, nutraceuticals, and pharmaceuticals," Mr. Carr
continued. "Furthermore, Elizabeth's experience in portfolio
management for innovation, commercialization, and product
development will bolster our plant chemistry manufacturing and
production capabilities. Both hires are important steps in
executing on our business plan and key milestone achievements."
Ms. Boot most recently served as Managing Director, Natural
Innovation & Operation at Green Line. Prior to that, she served
as VP Sales & Marketing at Bio Component Research, and Global
Manager, Technical Marketing at Lonza Consumer Care and at Arch
Personal Care Products. Previously, Ms. Boot held several marketing
manager and global product roles at Croda Inc., GE Advanced
Materials, and Brooks Industries, Inc. Ms. Boot holds a B.S. in
Biochemistry from St. Andrews Presbyterian
College.
Ms. Teigland joins Calyxt from Agropour Ingredients, where she
served as Director of Protein Research and led a cross-functional,
global team with ingredient and reliable method development. Prior
to that, she served as Research Scientist at Saputo Dairy Foods
USA, and as Field Application
Specialist at m2p-labs GmbH. Previously, Ms. Teigland held various
biotechnology and chemistry roles at Cargill, Inc. Ms. Teigland
holds a B.S. in Biochemistry and Chemistry from University of Iowa and a M.S. in Chemistry and
Microbiology from University of Oregon.
About Calyxt
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology
company. The Company leverages its proprietary
PlantSpring™ technology platform to engineer plant metabolism
to produce innovative high value plant-based chemistries for use in
customers' materials and products. As plant-based solutions, the
Company's synthetic biology products can be used in helping
customers meet their sustainability targets and financial goals.
Calyxt's diversified offerings are primarily delivered through its
proprietary BioFactory™ production system. For more information,
visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt
® logo are trademarks of Calyxt, Inc. Any other trademarks
belong to their respective owners.
Contacts
|
Calyxt Media
Contact:
|
Calyxt Investor
Relations Contact:
|
David Rosen/ John
Garabo/ Michael Barron Argot Partners
(212)
600-1902
media@calyxt.com
|
Kimberly Minarovich/
Cameron Willis
Argot Partners
(212)
600-1902
investors@calyxt.com
|
Calyxt Business
Development Contact:
|
|
Gerry Nuovo
Senior Vice President
of Business Development
(612)
427-7881
contact@calyxt.com
|
|
Forward-Looking Statements
This communication contains "forward-looking statements" within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify these statements by forward-looking words such as
"anticipates," "believes," "continue," "estimates," "expects,"
"intends," "may," "might," "plans," "predicts," "projects,"
"should," "targets," "will," or the negative of these terms and
other similar terminology. Forward-looking statements in this press
release include statements about the Company's future financial
performance, including its cash runway; its product pipeline and
development; its business model and strategies for the development,
commercialization and sales of commercial products; commercial
demand for its synthetic biology solutions; the development and
deployment of its PlantSpring technology platform; its ability to
deploy and leverage its artificial intelligence and machine
learning (AIML) capabilities; the ability to scale production
capability for its BioFactory production system; potential
development agreements, partnerships, customer relationships, and
licensing arrangements and their contribution to its financial
results, cash usage, and growth strategies; the potential impact of
the COVID-19 pandemic on its business and operating results; and
anticipated trends in its business. These and other forward-looking
statements are predictions and projections about future events and
trends based on the Company's current expectations, objectives, and
intentions and are premised on current assumptions. The Company's
actual results, level of activity, performance, or achievements
could be materially different than those expressed, implied, or
anticipated by forward-looking statements due to a variety of
factors, including, but not limited to: the impact of increased
competition, including competition from a broader array of
synthetic biology companies; competition for customers, partners,
and licensees and the successful execution of development and
licensing agreements; disruptions at its key facilities, including
disruptions impacting its BioFactory production system; flaws in
AIML algorithms, insufficiency of data inputs required by such
algorithms, and human error in interacting with AIML; changes in
customer preferences and market acceptance of its products; changes
in market consensus as to what attributes are required for a
product to be considered "sustainable"; the impact of adverse
events during development, including unsuccessful pilot production
of plant-based chemistries or field trials; the impact of improper
handling of its product candidates during development; failures by
third-party contractors; inaccurate demand forecasting or milestone
and royalty payment projections; the effectiveness of
commercialization efforts by commercial partners or licensees;
disruptions to supply chains, including raw material inputs for its
BioFactory; the impact of changes or increases in oversight and
regulation; disputes or challenges regarding intellectual property;
proliferation and continuous evolution of new technologies;
management changes; dislocations in the capital markets; the
severity and duration of the evolving COVID-19 pandemic and the
resulting impact on macro-economic conditions; and other important
factors discussed under the caption entitled "Risk Factors" in the
Company's Annual Report on Form 10-K. Any forward-looking
statements made by management of the Company are based only on
currently available information and speak only as of the date of
this communication. Except as otherwise required by securities and
other applicable laws, the Company does not assume any obligation
to publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calyxt-announces-strategic-hires-in-business-development-and-manufacturing-301532752.html
SOURCE Calyxt, Inc.